EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy

Most Arifa Sultana, Vijay Hegde

Frontiers in Genetics · 19.11.2026 · 17

DOI: 10.3389/fgene.2026.2002211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 19.11.2026. Verfasst von Most Arifa Sultana und 1 weiteren Autor:innen. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, and neuronal impairment. Natural antioxidants such as malvidin and N-acetylcysteine (NAC) exhibit antioxidant and anti-inflammatory properties, thereby help reduce reactive oxygen species (ROS) and support cellular redox balance by strengthening endogenous antioxidant defenses under conditions of oxidative stress and inflammation. By concurrently targeting oxidative stress, mitochondrial dysfunction, and neuroinflammation, these compounds could be promising candidates as multi-pathway metabolic stabilizers capable of mitigating AD pathology. Nonetheless, the therapeutic efficacy of such bioactive compounds is frequently constrained by their poor stability, rapid degradation, lower bioavailability and inefficient delivery to target tissues. Nanoliposome-based delivery systems can address these limitations by offering enhanced biocompatibility, improved stability, and efficient site-specific delivery of vulnerable bioactive compounds. This review summarizes the molecular mechanisms underlying mitochondrial dysfunction in AD, examines the individual neuroprotective effects of malvidin and NAC, and highlights the rational and emerging potential of malvidin-loaded and NAC-loaded nanoliposomes as two distinct targeted strategies for attenuating mitochondrial dysfunction in AD. This distinction provides a framework for considering each compound as an independent candidate for further investigation in AD-related therapeutic research.

Zitieren

APA

Sultana, M. A., & Hegde, V. (2026). Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.2002211

Vancouver

Sultana MA, Hegde V. Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.2002211

BibTeX
@article{Sultana2026,
  author = {Sultana, Most Arifa and Hegde, Vijay},
  title = {Nanoliposome-based malvidin or N-acetylcysteine therapeutics for attenuating mitochondrial dysfunction in Alzheimer’s disease: a targeted strategy},
  journal = {Frontiers in Genetics},
  year = {2026},
  volume = {17},
  doi = {10.3389/fgene.2026.2002211}
}
Kostenlos starten →